ATNM Actinium

Watchlist

12.080

-0.130-1.06%

Close 02/06 16:00 ET

High

12.460

Open

12.300

Turnover

3.13M

Low

11.940

Pre Close

12.210

Volume

257.88K

Intraday

Price Forecast

Comment

Announcement

Actinium Pharmaceuticals Signs R&D Deal With National Cancer Institute to Develop Actimab-A
09:00 AM EST, 02/06/2023 (MT Newswires) -- Actinium Pharmaceuticals (ATNM) said Monday that it has signed a cooperative research and development agreement with the National Cancer Institute to develop
02-06 09:03 ET
Actinium Signs Cooperative Research and Development Agreement With National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies
Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Le
02-06 07:34 ET
Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference
01-17 07:35 ET
Actinium Pharmaceuticals' Phase 3 Trial Data for Iomab-B Accepted for Presentation at Medical Conference
01:31 PM EST, 01/12/2023 (MT Newswires) -- Actinium Pharmaceuticals (ATNM) said Thursday data from its phase 3 trial of Iomab-B for acute myeloid leukemia have been accepted as a late-breaker presenta
01-12 01:32 ET
Fusion Pharmaceuticals Enters Partnership With BWX Technologies Unit for Actinium-225 Supply
03:13 AM EST, 01/06/2023 (MT Newswires) -- Fusion Pharmaceuticals (FUSN) has entered into a preferred partner agreement with BWX Technologies (BWXT) subsidiary BWXT Medical for the supply of actinium-
01-06 03:14 ET
Fusion Pharmaceuticals, BWXT Medical Announce Actinium-225 Partnership To Scale Supply For Developing Targeted Alpha Therapies
Fusion Pharmaceuticals, BWXT Medical Announce Actinium-225 Partnership To Scale Supply For Developing Targeted Alpha Therapies
01-05 05:04 ET
Analysts' Top Healthcare Picks: Pfizer (PFE), Actinium Pharmaceuticals (ATNM)
12-13-2022 09:05:14 ET
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients With Prior Venetoclax Treatment And/or With a TP53 Mutation From the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
12-12-2022 08:05:41 ET
Actinium Pharma Announces Research Collaboration With Columbia University To Study Actimab-A
12-08-2022 07:55:23 ET
Actinium, Columbia University to Study Actimab-A in AML Patients
12-08-2022 07:45:42 ET

Company Overview More

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2000 and is headquartered in New York, NY.

CEO： Mr. Sandesh Seth

Market： AMEX

Listing Date： 03/26/2014

Paper Trade More

Direction

Buy

Sell

Types

LMT Order

Price

QTY

Amount

Get Started

Hot List

TradeSearchNews

SymbolLatest price%Chg

Watchlist